Bibliographic record

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M. New England Journal of Medicine 2023

Document identifier: CEI-BR-120
Series: Bibliographic record
Version: 1.0
Published: 30 Jul 2026
Last reviewed: 30 Jul 2026
Certainty: Not rated

§1Bibliographic record

§1.1Record

Authors: Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M
Title: Daily oral GLP-1 receptor agonist orforglipron for adults with obesity
Source: New England Journal of Medicine
Year: 2023
Volume, issue, pages: 389(10):877–888
Digital object identifier: 10.1056/NEJMoa2302392
PubMed identifier: 37342922
Record type: Journal article
Institute identifier: CEI-BR-120

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

Document	Series
Monograph: Orforglipron	Compound monograph
Synthesis: Orforglipron in type 2 diabetes mellitus: effect on the anchor outcome	Evidence synthesis
Synthesis: Orforglipron in obesity and overweight in adults: effect on the…	Evidence synthesis
Synthesis: Orforglipron in type 2 diabetes mellitus: tolerability and…	Evidence synthesis
Synthesis: Orforglipron in obesity and overweight in adults: tolerability and…	Evidence synthesis
Synthesis: Orforglipron in type 2 diabetes mellitus: durability of effect	Evidence synthesis
Synthesis: Orforglipron in obesity and overweight in adults: durability of effect	Evidence synthesis
7 citing documents.

§1.3Subject tags

orforglipron obesity ATTAIN

Compound Evidence Institute · CEI-BR-120 · https://compoundevidence.com/bibliography/wharton2023/ · retrieved 30 July 2026